System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Research Support, Non-U.S. Gov't Epublish 9 citations

PubMed: 38433840 DOI: 10.3389/fimmu.2024.1330021

Gut microbiota and its metabolic products in acute respiratory distress syndrome.

Front Immunol 15:1330021

Authors: Dong-Wei Zhang, Jia-Li Lu, Bi-Ying Dong, Meng-Ying Fang, Xia Xiong, Xue-Jun Qin, Xian-Ming Fan

Affiliations

  • Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Inflammation & Allergic Diseases Research Unit, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Department of Respiratory and Critical Care Medicine, Liuzhou People's Hospital, Guangxi Medical University, Liuzhou, Guangxi, China. Key Laboratory of Diagnosis, Treatment and Research of Asthma and Chronic Obstructive Pulmonary Disease, Liuzhou, Guangxi, China.
  • Department of Respiratory and Critical Care Medicine, Liuzhou People's Hospital, Guangxi Medical University, Liuzhou, Guangxi, China. Key Laboratory of Diagnosis, Treatment and Research of Asthma and Chronic Obstructive Pulmonary Disease, Liuzhou, Guangxi, China.
  • Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Inflammation & Allergic Diseases Research Unit, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
  • Department of Dermatology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
  • Department of Respiratory and Critical Care Medicine, Liuzhou People's Hospital, Guangxi Medical University, Liuzhou, Guangxi, China.
  • Key Laboratory of Diagnosis, Treatment and Research of Asthma and Chronic Obstructive Pulmonary Disease, Liuzhou, Guangxi, China.

Abstract

The prevalence rate of acute respiratory distress syndrome (ARDS) is estimated at approximately 10% in critically ill patients worldwide, with the mortality rate ranging from 17% to 39%. Currently, ARDS mortality is usually higher in patients with COVID-19, giving another challenge for ARDS treatment. However, the treatment efficacy for ARDS is far from satisfactory. The relationship between the gut microbiota and ARDS has been substantiated by relevant scientific studies. ARDS not only changes the distribution of gut microbiota, but also influences intestinal mucosal barrier through the alteration of gut microbiota. The modulation of gut microbiota can impact the onset and progression of ARDS by triggering dysfunctions in inflammatory response and immune cells, oxidative stress, cell apoptosis, autophagy, pyroptosis, and ferroptosis mechanisms. Meanwhile, ARDS may also influence the distribution of metabolic products of gut microbiota. In this review, we focus on the impact of ARDS on gut microbiota and how the alteration of gut microbiota further influences the immune function, cellular functions and related signaling pathways during ARDS. The roles of gut microbiota-derived metabolites in the development and occurrence of ARDS are also discussed.

MeSH

Mortality, Immune System Diseases, Microbiota, Stress, Physiological, Cells, Respiratory Distress Syndrome, Prevalence, Gastrointestinal Microbiome, Covid-19

Cited by